Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 45.15 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 64.32 | Oscillator | Neutral |
| Williams %R (14) | -24.57 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.62 (Hist 0.16) | Oscillator | Buy |
| Average Directional Index (14) | 26.41 (+DI 16.7 / -DI 21.6) | Trend | Strong Sell |
Current price $10.53
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Mar 13, 26 |
| EMA 20 | 10.61 | MA | Sell |
| SMA 20 | 10.44 | MA | Buy |
| EMA 50 | 11.78 | MA | Strong Sell |
| SMA 50 | 12.39 | MA | Strong Sell |
| SMA 200 | 14.35 | MA | Strong Sell |
| Oppenheimer |
| maintain |
| Outperform |
| Outperform |
| Jan 22, 26 | Jefferies | maintain | Buy | Buy |
| Jan 21, 26 | Oppenheimer | maintain | Outperform | Outperform |
| Jan 21, 26 | Barclays | maintain | Overweight | Overweight |
| Jan 20, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 20, 25 | Mizuho | maintain | Outperform | Outperform |
| May 9, 25 | Oppenheimer | maintain | Outperform | Outperform |
| Mar 26, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 26, 25 | Oppenheimer | maintain | Outperform | Outperform |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 11, 26 | Moore David Scott | director | P-Purchase | 21,700 @ $11.53 | $250.2K |
| Jun 11, 26 | Moore David Scott | director | A-Award | 15,000 @ $11.60 | $174.0K |
| Jun 11, 26 | Clark Ian T | director | A-Award | 15,000 @ $11.60 | $174.0K |
| Jun 11, 26 | Grais Linda | director | A-Award | 15,000 @ $11.60 | $174.0K |
| Jun 11, 26 | Thompson Peter A. | director, 10 percent owner: | A-Award | 15,000 @ $11.60 | $174.0K |
| Jun 11, 26 | Van Den Broek Richard | director | A-Award | 15,000 @ $11.60 | $174.0K |
| May 18, 26 | Miller Richard A Md | director, officer: President and CEO | P-Purchase | 1,932 @ $12.01 | $23.20K |
| May 18, 26 | Miller Richard A Md | director, officer: President and CEO | P-Purchase | 5,000 @ $12.05 | $60.25K |
TTM vs. 5-year historical average (annual ratios)
| Metric | CRVS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -16.5x | -10.4x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -14.1x | EPS est. -0.75 | In line |
| Price / Book | 4.3x | 4.8x | In line |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -16.8x | -9.9x | Elevated |
| Return on equity | -36.1% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.00 | 0.03 | Conservative |
| Piotroski / Altman Z | 2/9 | Z 35.84 | Safe zone |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| SC 13G | Aug 7, 2026 | 2026-08-07 09:16:39 | View |
| 10-Q | Aug 6, 2026 | 2026-08-06 16:04:22 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 16:02:32 | View |
| SC 13G/A | Jul 27, 2026 | 2026-07-27 16:25:28 | View |
| 8-K | Jul 22, 2026 | 2026-07-22 16:02:21 | View |
| 4 | Jun 15, 2026 | 2026-06-15 17:12:29 | View |
| 4 | Jun 15, 2026 | 2026-06-15 17:10:06 | View |
| 4 | Jun 15, 2026 | 2026-06-15 17:08:12 | View |
| 4 | Jun 15, 2026 | 2026-06-15 17:06:45 | View |
| 4 | Jun 15, 2026 | 2026-06-15 17:04:07 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS - Get Free Report)'s stock price gapped up before the market opened on Tuesday. The stock had previously closed at $11.87, but opened at $12.37. Corvus Pharmaceuticals shares last traded at $11.8020, with a volume of 159,690 shares changing hands. Wall Street Analysts Forecast Growth A number of brokerages have recently
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the 2026 Cantor Global Healthcare Conference, which is being held in New York, NY. The fireside chat will be on Thursday, September 10, 2026 at 1:00 pm ET (10:00 am PT).
Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 2 trial in atopic dermatitis and planned trials for hidradenitis suppurativa and asthma Data in T cell lymphoma demonstrated anti-tumor activity based on tumor intrinsic and tumor extrinsic effects on microenvironment Highlights ITK inhibition novel mechanism of action, aligned with recently presented immunologic and biomarker data from the soquelitinib Phase 1 atopic dermatitis trial SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the publication of peer-reviewed final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma.
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
Corvus Pharmaceuticals NASDAQ: CRVS reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected milestones across programs in peripheral T-cell lymphoma, atopic dermatitis, hidradenitis suppurativa and asthma.
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track Soquelitinib's potential in atopic dermatitis and broader immunology and inflammation indications supported by Phase 1 clinical, immunologic and biomarker data presented at the Society for Investigative Dermatology (SID) annual meeting Cash, cash equivalents and marketable securities of $215.2 million at June 30, 2026, providing runway into 2Q28 Conference call and webcast today at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2026.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -0.16 | -0.19 | Miss -19.4% | — |
| May 7, 2026 | -0.14 | -0.15 | Miss -7.1% | — |
| Mar 12, 2026 | -0.14 | -0.15 | Miss -7.1% | — |
| Nov 4, 2025 | -0.14 | -0.12 | Beat 14.3% | — |
| Aug 7, 2025 | -0.13 | -0.10 | Beat 23.1% | — |
| May 8, 2025 | -0.13 | -0.13 | Beat 0.0% | — |